Abstract
Randomized clinical trials have shown that newly discharged and symptomatic patients with chronic heart failure (CHF) benefit from follow-up in a specialized heart failure clinic (HFC). Clinical stable and educated patients are usually discharged from the HFC when on optimal therapy. It is unknown if risk stratification using natriuretic peptides could identify patients who would benefit from longer-term follow-up. Furthermore, data on the use of natriuretic peptides for monitoring of stable patients with CHF are sparse.
Originalsprog | Engelsk |
---|---|
Tidsskrift | American Heart Journal |
Vol/bind | 156 |
Udgave nummer | 4 |
Sider (fra-til) | 649-55 |
Antal sider | 7 |
ISSN | 0002-8703 |
Status | Udgivet - okt. 2008 |